A few studies have already reported the programmed death-ligand 1 (PD-L1) and PD-L2 expression on tumor cells and tumor-infiltrating immune cells in PCNSL [3–6], but the expression of these two biomarkers in peritumoral tissue remains unclear. This evidence concerns the gene PDCD1LG2 and neoplasm.